A5016781466- Multiple Sclerosis Research Studies
- Polyomavirus and related diseases
- Parkinson's Disease Mechanisms and Treatments
- Alzheimer's disease research and treatments
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Herpesvirus Infections and Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Immunodeficiency and Autoimmune Disorders
- Cytokine Signaling Pathways and Interactions
- Plant Virus Research Studies
- Chronic Disease Management Strategies
- Cerebrovascular and genetic disorders
- Neurogenesis and neuroplasticity mechanisms
Amsterdam Neuroscience
2023-2025
Vrije Universiteit Amsterdam
2023-2025
Amsterdam University Medical Centers
2023-2025
Radboud University Nijmegen
2023-2024
Radboud University Medical Center
2023-2024
Objective Cerebral small vessel disease (SVD) is associated with motor impairments and parkinsonian signs cross‐sectionally, however, there are little longitudinal data on whether SVD increases risk of incident parkinsonism itself. We investigated the relation between baseline severity as well progression, over a follow‐up 14 years. Methods This study included 503 participants SVD, without at baseline, from RUN DMC prospective cohort study. Baseline inclusion was performed in 2006 took place...
Extended interval dosing (EID) of natalizumab is a promising strategy to optimise treatment in multiple sclerosis (MS). Personalised EID by therapeutic drug monitoring can enable further extension intervals.
Abstract Introduction The PRIME-NL study prospectively evaluates a new integrated and personalized care model for people with parkinsonism, including Parkinson’s disease, in selected region (PRIME) the Netherlands. We address generalizability sources of selection confounding bias by examining baseline 1-year compliance data. Methods First, we assessed regional differences between PRIME usual (UC) using healthcare claims data almost all disease Netherlands (the source population). Second,...
This cross-sectional study examines the increase in positive results for John Cunningham virus antibodies and higher risk progressive multifocal leukoencephalopathy among patients with multiple sclerosis receiving natalizumab.
ABSTRACT Intravenous natalizumab is an effective treatment for relapsing–remitting multiple sclerosis. However, the standard interval of 4 weeks may be excessive many patients. Personalized extension using therapeutic drug monitoring (TDM) can result in adequate exposure while reducing hospital visits and healthcare costs. Here, we investigate to which extent TDM‐guided personalized dosing benefit from model‐informed precision (MIPD). Individual posterior PK estimates were derived patient...
Background Natalizumab is a highly effective drug for patients with relapsing-remitting multiple sclerosis (MS). A disadvantage of this treatment the risk progressive multifocal leukoencephalopathy in who are seropositive John Cunningham virus (JCV). JCV seroconversion rates increase under natalizumab compared non-natalizumab using controls. The aim study was to assess whether lower trough concentrations associated reduced higher concentrations. Methods Two overlapping cohorts treated...
Background: Biomarkers of neuronal and axonal damage (serum neurofilament light (sNfL) serum glial fibrillary acidic protein (sGFAP)) may provide insight into the aetiology natalizumab wearing-off symptoms (WoSs). Objectives: We investigated longitudinal association between predictive value sNfL sGFAP occurrence WoS in MS patients treated with natalizumab. Methods: performed measurements NEXT-MS trial participants who completed a questionnaire about WoS. Results: A total 364 were included....
Background and objectivesWearing-off symptoms during natalizumab treatment in multiple sclerosis are characterized by an increase of MS-related prior to administration. The influence extended interval dosing (EID) on wearing-off important consider, as this might cause hesitancy initiating or continuing EID.MethodsParticipants the NEXT-MS trial, which intervals adjusted based drug concentrations, were divided into two groups: group containing participants with at least one week additional...